Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

• Status: Recruiting
• Trial end date: 2022-05-15

Summary

An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Scandion Oncology A/S
• Collaborator: Alcedis GmbH
• Treatments: Gemcitabine; Paclitaxel